Cargando…

Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses

PURPOSE: In recent years, many meta-analyses of triple-negative breast cancer (TNBC) treatment have been published; however, these studies still lack systematic summary. Therefore, the aim of this study is to summarize and evaluate the evidence level and efficacy of treatment for TNBC. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jianyun, Zhu, Changtai, Wang, Gaofeng, Gu, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252584/
https://www.ncbi.nlm.nih.gov/pubmed/35795302
http://dx.doi.org/10.2147/IJGM.S370351
_version_ 1784740296757608448
author Yin, Jianyun
Zhu, Changtai
Wang, Gaofeng
Gu, Jianwei
author_facet Yin, Jianyun
Zhu, Changtai
Wang, Gaofeng
Gu, Jianwei
author_sort Yin, Jianyun
collection PubMed
description PURPOSE: In recent years, many meta-analyses of triple-negative breast cancer (TNBC) treatment have been published; however, these studies still lack systematic summary. Therefore, the aim of this study is to summarize and evaluate the evidence level and efficacy of treatment for TNBC. MATERIALS AND METHODS: Retrospective and prospective studies on treatment of TNBC were searched in the PubMed, Embase, and Cochrane Library databases. The literature search deadline was June 30, 2021. Two investigators independently screened the literature and extracted the data. In addition, the joint World Health Organization–United Nations Food and Agriculture Organization expert consultation was used to evaluate the validity of the evidence. RESULTS: A total of 28 meta-analyses were included in this study. The treatment interventions for TNBC mainly included surgery, chemotherapy (CT), radiotherapy, molecular targeted therapy, immunotherapy, zoledronic acid, and gonadotropin-releasing hormone (GnRH) analog. Platinum improves the pathological complete response (PCR) rate of patients treated with neoadjuvant chemotherapy (NACT), the objective remission rate (ORR) and overall survival (OS) in patients with metastatic triple-negative breast cancer. Capecitabine improves disease-free survival (DFS) and OS in patients treated with adjuvant CT. Bevacizumab was added to NACT to improve the PCR rate in patients. Immunotherapy improves the PCR rate in patients treated with NACT. The improvement in PCR rate in patients with high Ki67 expression treated with neoadjuvant therapy is highly suggestive. Other interventions had suggestive or weak evidence. CONCLUSION: Among the strategies for treating TNBC, platinum, bevacizumab, and immunotherapy can lead to better PCR rates as part of a NACT regimen. Capecitabine as adjuvant CT and platinum in the treatment of metastatic TNBC can benefit patients’ survival. However, the effectiveness of other interventions for TNBC is not yet clear. Further research is needed in the future to obtain more reliable clinical evidence.
format Online
Article
Text
id pubmed-9252584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92525842022-07-05 Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses Yin, Jianyun Zhu, Changtai Wang, Gaofeng Gu, Jianwei Int J Gen Med Review PURPOSE: In recent years, many meta-analyses of triple-negative breast cancer (TNBC) treatment have been published; however, these studies still lack systematic summary. Therefore, the aim of this study is to summarize and evaluate the evidence level and efficacy of treatment for TNBC. MATERIALS AND METHODS: Retrospective and prospective studies on treatment of TNBC were searched in the PubMed, Embase, and Cochrane Library databases. The literature search deadline was June 30, 2021. Two investigators independently screened the literature and extracted the data. In addition, the joint World Health Organization–United Nations Food and Agriculture Organization expert consultation was used to evaluate the validity of the evidence. RESULTS: A total of 28 meta-analyses were included in this study. The treatment interventions for TNBC mainly included surgery, chemotherapy (CT), radiotherapy, molecular targeted therapy, immunotherapy, zoledronic acid, and gonadotropin-releasing hormone (GnRH) analog. Platinum improves the pathological complete response (PCR) rate of patients treated with neoadjuvant chemotherapy (NACT), the objective remission rate (ORR) and overall survival (OS) in patients with metastatic triple-negative breast cancer. Capecitabine improves disease-free survival (DFS) and OS in patients treated with adjuvant CT. Bevacizumab was added to NACT to improve the PCR rate in patients. Immunotherapy improves the PCR rate in patients treated with NACT. The improvement in PCR rate in patients with high Ki67 expression treated with neoadjuvant therapy is highly suggestive. Other interventions had suggestive or weak evidence. CONCLUSION: Among the strategies for treating TNBC, platinum, bevacizumab, and immunotherapy can lead to better PCR rates as part of a NACT regimen. Capecitabine as adjuvant CT and platinum in the treatment of metastatic TNBC can benefit patients’ survival. However, the effectiveness of other interventions for TNBC is not yet clear. Further research is needed in the future to obtain more reliable clinical evidence. Dove 2022-06-30 /pmc/articles/PMC9252584/ /pubmed/35795302 http://dx.doi.org/10.2147/IJGM.S370351 Text en © 2022 Yin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Yin, Jianyun
Zhu, Changtai
Wang, Gaofeng
Gu, Jianwei
Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title_full Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title_fullStr Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title_full_unstemmed Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title_short Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
title_sort treatment for triple-negative breast cancer: an umbrella review of meta-analyses
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252584/
https://www.ncbi.nlm.nih.gov/pubmed/35795302
http://dx.doi.org/10.2147/IJGM.S370351
work_keys_str_mv AT yinjianyun treatmentfortriplenegativebreastcanceranumbrellareviewofmetaanalyses
AT zhuchangtai treatmentfortriplenegativebreastcanceranumbrellareviewofmetaanalyses
AT wanggaofeng treatmentfortriplenegativebreastcanceranumbrellareviewofmetaanalyses
AT gujianwei treatmentfortriplenegativebreastcanceranumbrellareviewofmetaanalyses